英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:

perceiving    音标拼音: [pɚs'ivɪŋ]
感知

感知

Perceive \Per*ceive"\ (p[~e]r*s[=e]v"), v. t. [imp. & p. p.
{Perceived} (p[~e]r*s[=e]vd"); p. pr. & vb. n. {Perceiving}.]
[OF. percevoir, perceveir, L. percipere, perceptum; per (see
{Per-}) capere to take, receive. See {Capacious}, and cf.
{Perception}.]
1. To obtain knowledge of through the senses; to receive
impressions from by means of the bodily organs; to take
cognizance of the existence, character, or identity of, by
means of the senses; to see, hear, or feel; as, to
perceive a distant ship; to perceive a discord. --Reid.
[1913 Webster]

2. To take intellectual cognizance of; to apprehend by the
mind; to be convinced of by direct intuition; to note; to
remark; to discern; to see; to understand.
[1913 Webster]

Jesus perceived their wickedness. --Matt. xxii.
18.
[1913 Webster]

You may, fair lady,
Perceive I speak sincerely. --Shak.
[1913 Webster]

Till we ourselves see it with our own eyes, and
perceive it by our own understandings, we are still
in the dark. --Locke.
[1913 Webster]

3. To be affected of influented by. [R.]
[1913 Webster]

The upper regions of the air perceive the collection
of the matter of tempests before the air here below.
--Bacon.
[1913 Webster]

Syn: To discern; distinguish; observe; see; feel; know;
understand.

Usage: To {Perceive}, {Discern}. To perceive a thing is to
apprehend it as presented to the senses or the
intellect; to discern is to mark differences, or to
see a thing as distinguished from others around it. We
may perceive two persons afar off without being able
to discern whether they are men or women. Hence,
discern is often used of an act of the senses or the
mind involving close, discriminating, analytical
attention. We perceive that which is clear or obvious;
we discern that which requires much attention to get
an idea of it. "We perceive light, darkness, colors,
or the truth or falsehood of anything. We discern
characters, motives, the tendency and consequences of
actions, etc." --Crabb.
[1913 Webster]


请选择你想看的字典辞典:
单词字典翻译
perceiving查看 perceiving 在百度字典中的解释百度英翻中〔查看〕
perceiving查看 perceiving 在Google字典中的解释Google英翻中〔查看〕
perceiving查看 perceiving 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • FDA approves cemiplimab-rwlc for adjuvant treatment of . . .
    On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc ) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma
  • FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment . . .
    FDA approved of Regeneron Pharmaceutical’s Libtayo (cemiplimab-rwlc)as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) who are at an increased risk of recurrence following surgery and radiation 1 Libtayo was reviewed by FDA under Priority Review, a method reserved for medicines representing a potential improvement in efficacy or safety in treatments of
  • Libtayo (cemiplimab-rwlc) FDA Approval History - Drugs. com
    Libtayo (cemiplimab-rwlc) is a programmed death receptor-1 (PD-1) blocking antibody for the treatment of cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC)
  • label - Food and Drug Administration
    During the treatment period ranging from 8 to 19 months in 5 clinical studies, the incidence of anti-cemiplimab-rwlc antibodies in LIBTAYO-treated patients was 2% (22 1029)
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    The FDA evaluated Libtayo under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions
  • Behind the FDA Approval: Adjuvant Cemiplimab Shifts Treatment . . .
    Vishal A Patel, MD, discusses the FDA approval of cemiplimab in cutaneous squamous cell carcinoma On October 8, 2025, the US FDA approved the immunotherapy cemiplimab-rwlc (Libtayo) for adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence
  • FDA Approves Libtayo for Adjuvant Treatment of High-Risk CSCC
    Findings showed cemiplimab reduced the risk of disease recurrence or death by 68% compared with placebo The Food and Drug Administration (FDA) has approved Libtayo ® (cemiplimab-rwlc) for the adjuvant treatment of adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation
  • FDA Approves Cemiplimab for Adjuvant Cutaneous Squamous Cell . . .
    The US FDA has approved the supplemental biologics license application (sBLA) for cemiplimab-rwlc (Libtayo) as adjuvant treatment in adults with high-risk cutaneous squamous cell carcinoma (CSCC) 1 The sBLA approval was based on an extensive review of data from the pivotal phase 3 C-POST study (NCT03969004) which demonstrated a statistically significant and clinically meaningful improvement
  • LIBTAYO® (cemiplimab-rwlc) | Official HCP Website
    LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk CSCC See Important Safety full Prescribing Information
  • FDA Approves Cemiplimab (Libtayo) for Cutaneous Squamous Cell . . .
    The U S Food and Drug Administration approved adjuvant cemiplimab (Libtayo) for adults with cutaneous squamous cell carcinoma who are at a high risk for recurrence after surgery and radiation





中文字典-英文字典  2005-2009